Zhu F, et al. – The point of this study was to evaluate the dosimetric affect of intravenous contrast agent for pancreatic cancer radiotherapy treatment. A full analysis illustrated a negligible dose difference of less than 1% between contrast–enhanced computed tomography–based plan and non–contrast–enhanced computed tomography (CECT)–based plan. Thus, contrast–enhanced CT image can be applied directly for dose calculation of techniques of tomotherapy (TOMO) and volumetric–modulated arc therapy (VMAT) plans for pancreatic cancer. Moreover, it is unnecessary to scan twice then make a fusion of CECT and non–CECT, which would result to additional unnecessary radiation dose to patient and decrease work efficiency.